RECENT ADVANCES IN THE PHARMACEUTICAL MANAGEMENT OF DIABETES MELLITUS: EMERGING THERAPIES AND THE ROLE OF ONCE-WEEKLY INSULIN ICODEC (AWIQLI)

Diabetes mellitus, a multifaceted metabolic disorder, has emerged as a paramount global health concern, affecting over 463 million individuals worldwide. Diabetes causes serious consequences, such as retinopathy, nephropathy, and cardiovascular illnesses. It is characterized by persistent hyperglycemia brought on by either inadequate insulin secretion, impaired insulin action, or both. Consequently, scientists and or researchers will continue to find novel, safe, effective and affordable anti-diabetic medications. The goal of this review is to provide a through overview of the role that lifestyle changes play in managing diabetes, as well as day to day foods manage in diabetes mellitus. There are three types of 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus and gestational diabetes. In this condition Conventional insulin therapy generally requires daily injections, which may reduce treatment adherence in some patients. Traditional treatment includes metformin, sulfonylureas, thiazolidinedione’s, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists and insulin preparations. One of the important recent advances is insulin icodec, marketed as Awiqli, a long-acting basal insulin designed for once-weekly administration. Clinical studies have demonstrated that once-weekly insulin icodec can provide glycemic control comparable to commonly used once-daily basal insulins in adults with diabetes. Meta-analyses have also reported effective HbA1c reduction and similar overall safety compared with daily basal insulin, although hypoglycemia and other adverse effects remain important considerations. Awiqli (insulin icodec) was authorized in the European Union in 2024 and received US FDA approval on March 26, 2026, for improving glycemic control in adults with type 2 diabetes mellitus.

• Ahmad F and Joshi SH. (2023). Self-Care Practices and Their Role in the Control of Diabetes: A Narrative Review. Cureus., 15(7): e41409. doi: 10.7759/cureus.41409.
• Alcocer LA, Bryce A, De Padua Brasil D, Lara J, Cortes JM, Quesada D and Rodriguez P. (2023). The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines. Am Journal Cardiovascular Drugs, 23(6): 663-682.
• Aloke C, Egwu CO, Aja PM, Obasi NA, Chukwu J, Akumadu BO, Ogbu PN and Achilonu I. (2022). Current Advances in the Management of Diabetes Mellitus. Biomedicines, 10(10): 2436. doi: 10.3390/biomedicines10102436.
• Alzohairy MA. (2016). Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment. Evid Based Complement Alternat Med., 2016: 7382506. doi: 10.1155/2016/7382506.
• Ansari MA, Chauhan W, Shoaib S. et al. (2023). Emerging therapeutic options in the management of diabetes: recent trends, challenges and future directions. International Journal of Obesity, 47: 1179–1199. 
• Aradhana S, Manjula BL and Kumar S. (2022). Scientific validation of tribal claims on the plants used in diabetes by Santhal community, Mayurbhanj, Odisha, India. Medicinal Plants, 14(4): 513-517.
• Ayyanar M and Subash-Babu P. (2012). Syzygium cumini (L.) Skeels: a review of its phytochemical constituents and traditional uses. Asian Pac Journal Trop Biomed, 2(3): 240-246.
• World Health Organisation. Media centre, diabetes mellitus. 2018. Available from: URL:
  http://www.who.int/mediacentre/factsheets/fs138/en/.
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes
  care, 2014; 37(Suppl 1): 81-90.
• Abdelmoneim AS, Eurich DT, Gamble JM, et al. Use patterns of antidiabetic regimens by
  patients with type 2 diabetes. Canadian journal of diabetes, 2013; 37(6): 394-400.
• London Diabetes Centre. Worried about Diabetes? Available from: URL:
  https://londondiabetes.com/
• Ozougwu JC, Obimba KC, Belonwu CD, et al. The pathogenesis and pathophysiology of
  type 1 and type 2 diabetes mellitus. Journal of Physiology and Pathophysiology, 2013; 4(4):
  46-57.
• Baynes HW. Classification, pathophysiology, diagnosis and management of diabetes
  mellitus. J diabetes metab., 2015; 6(5): 1-9.
• Li S, Guo S, He F, et al. Prevalence of diabetes mellitus and impaired fasting glucose,
  associated with risk factors in rural Kazakh adults in Xinjiang, China. International journal of
  environmental research and public health, 2015; 12(1): 554-65.
• Gupta M, Singh R, Lehl SS. Diabetes in India: a long way to go. International Journal of
  Scientific Reports, 2015; 1(1): 1-2.
• Pareek H, Sharma S, Khajja BS, Jain K, Jain GC. Evaluation of hypoglycemic and anti
  hyperglycemic potential of Tridax procumbens (Linn.) BMC Complement Altern Med., 2009; 9: 48.
  doi:1186/1472-6882-9-48. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Craig ME, Hattersley A, Donaghue KC. Definition, epidemiology and classification of
  diabetes in children and adolescents. Pediatr Diabetes, 2009; 10: 3–12. doi:
  10.1111/j.1399-5448.2009.00568.x. [DOI] [PubMed] [Google Scholar]
• Thévenod F. Pathophysiology of diabetes mellitus type 2: Roles of obesity, insulin resistance
  and β-cell dysfunction. Front Diabetes Basel Karger, 2008; 19: 1–18. [Google Scholar]
• Patel DK, Kumar R, Prasad SK, Sairam K, Hemalatha S. Antidiabetic and in vitro antioxidant
  potential of Hybanthus enneaspermus (Linn) F. Muell in streptozotocin-induced diabetic rats.
  Asian Pac J Trop Biomed, 2011; 1: 316–322. doi: 10.1016/S2221-1691(11)60051-8. [DOI] [PMC
  free article] [PubMed] [Google Scholar]
• Patel DK, Kumar R, Prasad SK, Hemalatha S. Pedalium murex Linn (Pedaliaceae) fruits: A
  comparative antioxidant activity of its different fractions. Asian Pac J Trop Biomed, 2011; 1:      395–400. doi: 10.1016/S2221-1691(11)60087-7. [DOI] [PMC free article] [PubMed]